The company is doing well with its immunology and oncology drugs and has showed resilience against the competition from generic drugs in centralnervoussystem therapeutic area.
"Lilly understands how to build markets in centralnervoussystemdrugs, and they know how to establish a presence in the antidepressant space, " says Hazlett.